Cel-Sci/$CVM
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Cel-Sci
CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The company is focused on the development of the following product candidates and technologies: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; 2) LEAPS (Ligand Epitope Antigen Presentation System) technology, for the potential treatment of rheumatoid arthritis.
Ticker
$CVM
Sector
Primary listing
AMEX
Employees
44
Headquarters
Website
Cel-Sci Metrics
BasicAdvanced
$20m
-
-$3.32
0.60
-
Price and volume
Market cap
$20m
Beta
0.6
52-week high
$13.48
52-week low
$0.89
Average daily volume
353k
Financial strength
Current ratio
0.602
Quick ratio
0.395
Long term debt to equity
85.816
Total debt to equity
123.82
Interest coverage (TTM)
-43.92%
Profitability
EBITDA (TTM)
-20.176
Management effectiveness
Return on assets (TTM)
-70.28%
Return on equity (TTM)
-305.27%
Valuation
Price to book
1.41
Price to tangible book (TTM)
1.42
Price to free cash flow (TTM)
-0.469
Free cash flow yield (TTM)
-213.44%
Free cash flow per share (TTM)
-2.433
Growth
Earnings per share change (TTM)
-73.11%
3-year earnings per share growth (CAGR)
-48.65%
10-year earnings per share growth (CAGR)
-31.82%
Cel-Sci News
AllArticlesVideos
CEL-SCI Corporation Announces Pricing of Offering
Business Wire·3 weeks ago
CEL-SCI and Saudi Amarox to Conduct Signing Ceremony at BIO 2026 for Strategic Agreement to Advance Commercialization and Distribution of Multikine® in Saudi Arabia
Business Wire·3 weeks ago
CEL-SCI Announces Closing of Public Offering
Business Wire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs